A retrospective review combining observational data from three referral centres in Korea has underlined the potential benefits of the immunosuppressant drug mycophenolate mofetil (MMF) in patients with neuromyelitis optica (NMO). In a drug-efficacy analysis involving 58 patients with NMO, MMF treatment was associated with reduced relapse frequency, as well as stabilization or improvement of disability. The authors propose that the drug warrants futher investigation in a larger randomized clinical trial.